A Phase I, Single Arm, Multiple Dose, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Advanced Solid Tumors

Trial Profile

A Phase I, Single Arm, Multiple Dose, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs KN 035 (Primary)
  • Indications Liver cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors 3D Medicines
  • Most Recent Events

    • 08 Jan 2018 Planned number of patients changed from 36 to 60.
    • 08 Jan 2018 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 07 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top